SCHEMBL10150704

SCHEMBL10150704

C/N=C(/c1ccc(-c2ccccc2)cc1)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
KIF11 P52732 1/20 0.42
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
WDR5 P61964 1/20 0.39
PTPN5 P54829 1/20 0.39
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
MMP3 P08254 1/20 0.37
BCL2L1 Q07817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150694 0.88 CES1 (0.46) ALDH1A1GAAALOX15HSD17B10NPC1
SCHEMBL12770212 0.88 CES1 (0.46) ALDH1A1GAAALOX15HSD17B10NPC1
SCHEMBL10150741 0.85 GAA (0.50) ALDH1A1GAAALOX15HSD17B10CES1
SCHEMBL10150703 0.85 SMN1; SMN2 (0.41) SMN1; SMN2MAPTKIF11ALDH1A1L3MBTL1
SCHEMBL12994632 0.82 SMN1; SMN2 (0.39) SMN1; SMN2MAPTKIF11ALDH1A1L3MBTL1
SCHEMBL10239161 0.74 HPGD (0.42) SMN1; SMN2MAPTALDH1A1GAAALOX15
SCHEMBL12994634 0.74 HPGD (0.42) SMN1; SMN2MAPTALDH1A1GAAALOX15
SCHEMBL17865302 0.74 HDAC6 (0.42) SMN1; SMN2MAPTKIF11ALDH1A1GAA
SCHEMBL10138310 0.73 ALDH1A1 (0.47) SMN1; SMN2MAPTALDH1A1GAAALOX15
SCHEMBL10150702 0.71 SMN1; SMN2 (0.56) SMN1; SMN2MAPTALDH1A1HSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 SMN1; SMN2 1282/4885MAPT 3059/4885KIF11 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.